Evidence map›Paper›PMID 38666295›Full record

ArticleHistology and histopathology2024

Protection of Qingfei Xieding prescription from idiopathic pulmonary fibrosis by regulating renin-angiotensin and ferroptosis in MLE-12 cells.

Lifang Sun, Xinxin He, Jiao Kong, Jianying Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lifang SunDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
Xinxin HeSchool of Clinical Medicine, Hangzhou Medical College, Hangzhou, PR China.
Jiao KongThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, PR China.
Jianying ZhouDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China. zjyhz@zju.edu.cn.
Hangzhou Red Cross Hospital · CN

Funding

Zhejiang Provincial Natural Science Foundation of China LY21H010001Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project 2021ZB219
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a lifelong lung disease, but there is no specific drug for treatment. Qingfei Xieding prescription (QF) is active in the treatment of lung diseases. More comprehensive mechanisms over how QF exhibits anti-pulmonary fibrosis need to be elucidated. TGF-β was used to construct a pulmonary fibrosis cell model

Indexed as

Drugs, Chinese HerbalFerroptosisIdiopathic Pulmonary FibrosisRenin-Angiotensin SystemAnimalsBleomycinCell LineDisease Models, AnimalLungMaleMiceMice, Inbred C57BLReactive Oxygen SpeciesSignal TransductionTransforming Growth Factor betaBleomycinDrugs, Chinese HerbalReactive Oxygen SpeciesTransforming Growth Factor beta

Identifiers

PMID38666295
OpenAlexW4395677493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.